A comprehensive proteogenomic, immunopeptidomic, and metabolomic atlas decodes immunogenicity in cutaneous melanoma
Year: 2026
Type: article
Study design: Observational Study
Abstract: Cutaneous melanoma exhibits strong responses to immunotherapy, yet the system-level mechanisms linking mutational burden, genomic alterations, antigen landscapes, post-transcriptional and post-translational regulation, and immune outcomes remain incompletely defined. We profiled 183 cutaneous melanomas using 13 omic layers, including immunopeptidomics, metabolomics, protein ubiquitylation and glycosylation, to construct a holistic view of tumor immunogenicity. Mass spectrometry-based HLA-I immunopeptidomics revealed correlation between tumor antigens and CD8+ T-cell infiltration. Metabolomics revealed distinct ether-linked lipids and mitochondrial metabolic profiles between primary and metastatic tumors. Ubiquitylomics uncovered a subset of tumors associated with worse survival, characterized by high ubiquitylation of the IFN signaling pathway and ubiquitylation-dependent activation of AKT1. Glycoproteomic analyses identified GPNMB glycosylation as a key feature associated with sex-specific survival, linking this signal to a lysosome-associated program and suggesting potential sex-dependent differences in immunotherapy response. This multi-omic atlas of cutaneous melanoma illuminates mechanisms of immune evasion, informing treatment-relevant patient stratification in melanoma care.
Source: Cancer Discovery
Authors: Jianhui Gong(Formal analysis, Project administration, Writing – original draft), Francesca Petralia(Formal analysis, Project administration, Writing – original draft), Maria Virginia Ruiz Cuevas(Formal analysis, Writing – original draft), Nicole Tignor(Formal analysis, Writing – original draft), Raghav Jain(Formal analysis, Writing – original draft), Marina A. Gritsenko(Investigation), Shrabanti Chowdhury(Formal analysis, Writing – original draft), Reta Birhanu Kitata(Formal analysis, Investigation), Weiping Ma(Data curation, Formal analysis, Writing – original draft), Yi Hsiao, Yamei Deng, Karl R. Clauser(Formal analysis, Writing – original draft), Anna I. Byrd(Formal analysis, Writing – original draft), Azra Krek(Formal analysis, Writing – original draft), Susanne Ibing(Formal analysis, Writing – original draft), Lijun Chen(Investigation), Xiaoyu Song(Formal analysis, Methodology, Writing – original draft), Nicholas J. Day(Data curation, Investigation), Hyeyoon Kim(Data curation, Investigation), Yingwei Hu(Formal analysis), Karl K. Weitz(Investigation), Rosalie K. Chu(Investigation), Priscila M. Lalli(Investigation), Athena A. Schepmoes(Investigation), Josie G. Eder(Investigation), Tyler J. Sagendorf(Data curation), Vladislav A. Petyuk(Data curation, Supervision), Chaevien S. Clendinen(Data curation), Javier E. Flores(Data curation), Ronald J. Moore(Investigation, Supervision), Matthew E. Monroe(Data curation), Gabrielle M. Hernandez(Data curation, Investigation), Claudia Ctortecka, Eva K. Verzani(Data curation, Investigation), Isabelle E. Lippincott(Data curation, Investigation), Kristin G. Beaumont(Investigation, Writing – original draft), Yan-Chak Li(Software), Giacomo B. Marino(Formal analysis), Fengchao Yu(Formal analysis), Yuping Zhang(Formal analysis), Gabriel Cruz(Formal analysis), Noshad Hosseini(Formal analysis), Yuqing Shang(Formal analysis), Natalie M. Clark(Formal analysis), Chelsea Newton(Investigation), Meredith Freeman(Formal analysis), Yongchao Dou(Data curation), Seunghyuk Choi(Writing – review & editing), Michelle Aranha(Writing – review & editing), Nathan J. Edwards(Writing – review & editing), Eunkyung An(Writing – review & editing), Xu Zhang(Resources, Supervision), Ana I. Robles(Writing – review & editing), Alexander J. Lazar(Writing – review & editing), Tujin Shi, Li Ding(Writing – review & editing), Bing Zhang(Writing – review & editing), D. R. Mani(Supervision, Writing – review & editing), Gilbert S. Omenn(Supervision), Michael A. Gillette(Supervision, Writing – review & editing), Steven A. Carr(Investigation, Supervision), Saravana M. Dhanasekaran(Supervision, Writing – review & editing), Mehdi Mesri, Mathangi Thiagarajan(Investigation, Supervision), Alexey I. Nesvizhskii(Supervision, Writing – review & editing), Hui Zhang(Supervision, Writing – review & editing), Galen Hostetter, Avi Ma'ayan(Supervision, Writing – original draft, Writing – review & editing), Jennifer E. Kyle(Conceptualization, Supervision, Writing – original draft), Jennifer G. Abelin(Conceptualization, Supervision, Writing – original draft), Paul W. Harms(Conceptualization, Supervision, Writing – original draft), Amanda G. Paulovich(Conceptualization, Supervision, Writing – original draft), Diwakar Davar(Conceptualization, Supervision, Writing – original draft), Marcin P. Cieslik(Conceptualization, Supervision, Writing – original draft), Tao Liu(Conceptualization, Supervision, Writing – original draft), Pei Wang(Conceptualization, Supervision, Writing – original draft)
Institutions: University of Michigan, Icahn School of Medicine at Mount Sinai, Broad Institute, Pacific Northwest National Laboratory, Johns Hopkins Medicine, Duke-NUS Medical School, Sookmyung Women's University, SingHealth Duke-NUS Academic Medical Centre, Van Andel Institute, Washington University in St. Louis, Baylor College of Medicine, Georgetown University, National Cancer Institute, The University of Texas MD Anderson Cancer Center, Frederick National Laboratory for Cancer Research, Fred Hutch Cancer Center, University of Pittsburgh Medical Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: cutaneous melanoma, tumor immunogenicity, immunopeptidomics, CD8+ T cell infiltration, cancer metabolomics, ether lipids, mitochondrial metabolism, metastatic melanoma, protein ubiquitylation, interferon signaling, glycoproteomics, lysosomes, sex differences in survival, immune evasion, patient stratification, immunotherapy response
Open Access status: hybrid
Funders: Fred Hutchinson Cancer Research Center, University of Washington, Georgia Clinical and Translational Science Alliance, National Institutes of Health, Medical School, University of Michigan, National Cancer Institute, National Center for Advancing Translational Sciences, Office of Research Infrastructure Programs, National Institutes of Health
Awards: G1131636781, G1305388156, G1713994812, G2289013418, Big Omics Data Engine 2 Supercomputer, G447134329, G4681072085, G4689185066, G6177305277, COVID and Translational Science supercomputer (CATS), G8153424785, Center for comprehensive proteogenomic data analysis, Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies, Center for Advanced Multi-Omic Characterization of Cancer, Proteogenomic Predictors of Recurrence in Non-small Cell Lung Cancer, Conduits: Mount Sinai Health System Translational Science Hub, Michigan Center for Translational Cancer Proteogenomics, Proteogenomic translator for cancer biomarker discovery towards precision medicine, Center of Excellence for High Throughput Proteogenomic Characterization, Mayo Clinic Center for Clinical Proteomics, Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemia, iPGDAC, An Integrative Proteogenomic Data Analysis Center for CPTAC, Proteogenomic Characterization of Tumor Tissues and Preclinical Models with High Precision
OpenAlex ID: W7235155769
